Search Result

Results for "

ADP-induced aggregation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Adrenergic Receptor (1) Apoptosis (2) Bacterial (1) Cytochrome P450 (3) Drug Derivative (2) Drug Metabolite (2) Endogenous Metabolite (6) Integrin (1) Isotope-Labeled Compounds (4) NO Synthase (1) P2X Receptor (1) P2Y Receptor (28) PARP (1) Phosphodiesterase (PDE) (1) PPAR (1) Prostaglandin Receptor (3) Reference Standards (5) Src (1) Thrombin (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (41) Endocrinology (2) Inflammation/Immunology (3) Metabolic Disease (6) Neurological Disease (2)
Oligonucleotides:	Nucleotide Analogs (3) Adenine Nucleotide (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19638A

Cangrelor tetrasodium 4 Publications Verification AR-C69931MX tetrasodium	P2Y Receptor	Cardiovascular Disease Inflammation/Immunology
Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .

HY-17459

Clopidogrel hydrogen sulfate Maximum Cited Publications 30 Publications Verification (S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate	Cytochrome P450 P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC₅₀s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

HY-15284

Prasugrel 1 Publications Verification PCR 4099	P2Y Receptor	Cardiovascular Disease
Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-P0074

GPRP 3 Publications Verification Gly-Pro-Arg-Pro; Pefa 6003	Thrombin	Cardiovascular Disease
GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor) . GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of thrombin onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases .

HY-15284A

Prasugrel hydrochloride 1 Publications Verification PCR 4099 hydrochloride	P2Y Receptor	Cardiovascular Disease
Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-108658

MRS2500 tetraammonium	P2Y Receptor	Cardiovascular Disease
MRS2500 tetraammonium is a potent, selective and stable antagonist of the P2Y1 receptor (K_i=0.78 nM for recombinant human P2Y1 receptor). MRS2500 tetraammonium inhibits the ADP-induced aggregation of human platelets with an IC₅₀ value of 0.95 nM. Antithrombotic activity .

HY-W009276

γ-Linolenic Acid methyl ester Methyl GLA	Apoptosis	Cancer
γ-Linolenic Acid methyl ester (Methyl GLA) is an esterified version of γ-Linolenic Acid (GLA), which is an ω-6 fatty acid, serves as melanoma cell proliferation inhibitors. γ-Linolenic Acid methyl ester inhibits ADP-induced blood platelet aggregation and induces apoptosis .

HY-W250153

Adenosine 3'-phosphate 5'-phosphosulfate lithium	P2Y Receptor	Cardiovascular Disease
Adenosine 3'-phosphate 5'-phosphosulfate lithium, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

HY-123669A

trans-R-138727	P2Y Receptor	Cardiovascular Disease
Trans-R-138727 is the trans isomer of R-138727 (HY-123669). R-138727 is the active metabolite of the antiplatelet agent Prasugrel (HY-15284). R-138727 is an irreversible inhibitor for the platelet receptor P2Y12, and inhibits ADP-induced platelet activation and aggregation .

HY-19638

Cangrelor AR-C69931MX	P2Y Receptor	Cardiovascular Disease Inflammation/Immunology
Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist .

HY-N5021

Anhydrosafflor yellow B AHSYB	Others	Neurological Disease
Anhydrosafflor yellow B (AHSYB) is a quinochalcone C-glycoside isolated from Carthamus tinctorius. Anhydrosafflor yellow B inhibits ADP-induced platelet aggregation, exhibits significant anti-oxidative effects in vitro, and possesses certain activity against H₂O₂-induced cytotoxicity in cultured PC12 cells and primary neuronal cells .

HY-164090

Adenosine 3'-phosphate 5'-phosphosulfate	P2Y Receptor	Cardiovascular Disease
Adenosine 3'-phosphate 5'-phosphosulfate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

HY-N3228

Myrianthic acid	Others	Cardiovascular Disease
Myrianthic acid is a pentacyclic triterpenoid compound. Myrianthic acid can exist in the root wood of Myrianthus arboreus and the leaves of Campsis grandiflora. Myrianthic acid inhibits adrenaline-induced platelet aggregation, with a IC₅₀ of 46.2 μM for this activity. Myrianthic acid can be used in studies related to thrombosis .

HY-149454

P2Y1/P2Y12 antagonist-1 1 Publications Verification	P2Y Receptor	Cancer
P2Y1/P2Y12 antagonist-1 (compound 24w) is an orally available dual inhibitor of P2Y1 and P2Y12 with antiplatelet activity. P2Y1/P2Y12 antagonist-1 inhibits ADP-induced platelet aggregation in rabbit plasma with an IC₅₀ of 4.23 μM. P2Y1/P2Y12 antagonist-1 exhibits potent inhibitory effects in rat thrombosis model.

HY-15284S2

Prasugrel-d4 PCR 4099-d₄	P2Y Receptor	Cardiovascular Disease
Prasugrel-d₄ is the deuterium labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-N7614

Anemarrhenasaponin A2 1 Publications Verification Schidigerasaponin F2; Timosaponin AII	Others	Cardiovascular Disease
Anemarrhenasaponin A2 (Schidigerasaponin F2) is a steroidal saponin isolated from the rhizomes of Anemarrhena asphodeloides. Anemarrhenasaponin A2 inhibits ADP-induced platelet aggregation .

HY-119860

Ataprost ONO 41483	Drug Derivative	Cardiovascular Disease
Ataprost (ONO 41483) is an orally active Carboprostacyclin (HY-112322) analogue. Ataprost exhibits 2.6 times more active than Carboprostacyclin in inhibiting ADP-induced platelet aggregation in vitro. Ataprost has the ability to relieve coronary spasm .

HY-N9422

Adenosine 3'-phosphate 5'-phosphosulfate triethylamine	P2Y Receptor	Cardiovascular Disease
Adenosine 3'-phosphate 5'-phosphosulfate triethylamine, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate triethylamine can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate triethylamine is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate triethylamine can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

HY-113096

Prostaglandin D1 PGD1	Endogenous Metabolite	Metabolic Disease
Prostaglandin D1 is a prostanoid which causes contractile and relaxant on isolated human pial arteries, it is also an inhibitor of ADP-induced platelet aggregation with an IC₅₀ value of 320 ng/ml. Prostaglandin D1 can be used for metabolic research .

HY-108633

BYK 49187	PARP	Cancer
AR-C66096 (FPL 66096) tetrasodium is a selective platelet P2Y_T receptor antagonist. AR-C66096 tetrasodium effectively blocks ADP-induced platelet aggregation. AR-C66096 tetrasodium can be used in the research of thromboembolism .

HY-148300

AR-C66096	P2Y Receptor	Cardiovascular Disease
AR-C66096 is a potent and selective antagonist of the Gi-coupled P2Y12 receptor. AR-C66096 suppresses platelet thrombus stability under physiological flow conditions. AR-C66096 inhibits ADP-induced aggregation in whole blood aggregometry. AR-C66096 can be used for antithrombotic research .

HY-19638AR

Cangrelor tetrasodium (Standard) AR-C69931MX tetrasodium (Standard)	P2Y Receptor Reference Standards	Cardiovascular Disease Inflammation/Immunology
Cangrelor (tetrasodium) (Standard) is the analytical standard of Cangrelor (tetrasodium). This product is intended for research and analytical applications. Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .

HY-W250153A

Adenosine 3'-phosphate 5'-phosphosulfate lithium, hydrate	P2Y Receptor	Cardiovascular Disease
Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

HY-116850

Oxagrelate EG626; Phthalazinol; SC-32840	Phosphodiesterase (PDE)	Neurological Disease
Oxagrelate is a specific inhibitor of cyclic adenosine monophosphate phosphodiesterase and exhibits concentration-dependent inhibition of collagen- and ADP-induced platelet aggregation in vitro .

HY-P1702

GR83895	Integrin	Others
GR83895 is a RGD based peptide, and inhibits ADP-induced platelet aggregation of human gel-filtered platelets (IC₅₀= 0.9 μM) .

HY-N13135

Kadsutherin G	Others	Cardiovascular Disease
Kadsutherin G (compound 3) is a lignin isolated from Kadsura. Kadsutherin G inhibits adenosine diphosphate (ADP)-induced platelet aggregation by 33.1 % .

HY-N13134

Kadsutherin F	Others	Cardiovascular Disease
Kadsutherin F (compound 2) is a lignin that can be isolated from Kadsura. Kadsutherin F has an inhibitory effect on adenosine diphosphate (ADP)-induced platelet aggregation with an inhibition rate of 49.47% .

HY-15284B

Prasugrel (Maleic acid) PCR 4099 (Maleic acid)	P2Y Receptor	Cardiovascular Disease
Prasugrel (PCR 4099) Maleic acid is a thienopyridine and proagent, inhibits platelet function. Prasugrel Maleic acid is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-101370

2-Methylthio-ATP tetrasodium	P2X Receptor	Metabolic Disease
2-Methylthio-ATP tetrasodium is a non-specific P2-receptor agonist. 2-Methylthio-ATP tetrasodium causes noncompetitive inhibition of ADP-induced human platelet aggregation .

HY-113113

13,14-Dihydro PGE1 13,14-Dihydroprostaglandin E1	Endogenous Metabolite	Metabolic Disease
13,14-Dihydro PGE₁ is a metabolite of PGE₁ (Prostaglandin E1) which inhibits the ADP-induced platelet aggregation (ID₅₀ = 10.8 ng/mL platelet rich plasma) .

HY-N4266

Vinaginsenoside R8	Others	Cardiovascular Disease
Vinaginsenoside R8, a triterpenoid glycoside isolated from the rhizomes of Panacis majoris. Vinaginsenoside R8 displays activities against adenosine diphosphate (ADP)-induced platelet aggregation (IC₅₀=25.18 μM) .

HY-136142

Prasugrel chloride impurity	Drug Metabolite	Others
Prasugrel chloride impurity is a catp impurity of Prasugrel, exacted from patent US20130345428A1, line 0053. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S1

Prasugrel-d3 PCR 4099-d₃	P2Y Receptor	Cardiovascular Disease
Prasugrel-d₃ is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S

Prasugrel-d5 PCR 4099-d₅	Isotope-Labeled Compounds P2Y Receptor	Cardiovascular Disease
Prasugrel-d₅ is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-122048

AR-C67085 AR-C67085MX; PSB 0413; FPL 67085	P2Y Receptor	Cardiovascular Disease
AR-C67085 (PSB 0413; FPL 67085) is a potent platelet P_2T receptor antagonist with an pIC₅₀ value of 8.60. AR-C67085 inhibits ADP-induced platelet aggregation .

HY-W419570

(Rac)-BX 048	P2Y Receptor	Cardiovascular Disease
(Rac)-BX 048 is a BX 048 racemate. BX 048 is a P2Y12 receptor antagonist. BX 048 inhibits ADP-induced platelet aggregation in human, dog and rat whole blood. BX 048 also inhibits Arachidonic acid (HY-109590) induced platelet aggregation (IC₅₀ of 15 μM) .

HY-113723

MRS2298	P2Y Receptor	Cardiovascular Disease
MRS2298? is a potent acyclic P2Y1 receptor antagonist with a K_i of 29.6 nM. MRS2298 inhibits the ADP-induced aggregation of human platelets with an IC₅₀ of 62.8 nM. MRS2298 inhibits Ca ²⁺ rise in platelets with an IC₅₀ of 810 nM .

HY-15284R

Prasugrel (Standard) PCR 4099 (Standard)	Reference Standards P2Y Receptor	Cardiovascular Disease
Prasugrel (Standard) is the analytical standard of Prasugrel. This product is intended for research and analytical applications. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284AR

Prasugrel hydrochloride (Standard) PCR 4099 hydrochloride (Standard)	Reference Standards P2Y Receptor	Cardiovascular Disease
Prasugrel (hydrochloride) (Standard) is the analytical standard of Prasugrel (hydrochloride). This product is intended for research and analytical applications. Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S3

Prasugrel-13C6 PCR 4099-¹³C₆	Isotope-Labeled Compounds P2Y Receptor	Cardiovascular Disease
Prasugrel-13C6 is a deuterated labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-137591

13,14-Dihydro-15-keto-PGE1	Drug Metabolite	Endocrinology
13,14-Dihydro-15-keto-PGE1 is an inactive metabolite of PGE1. 13, 14-Dihydro-15-Keto-pGE1 inhibited platelet aggregation in ADP-induced human isolated platelet-rich plasma with IC₅₀ 14.8 μg/mL .

HY-113096S

Prostaglandin D1-d4 PGD1-d₄	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Prostaglandin D1-d₄ (PGD1-d₄) is deuterium labeled Prostaglandin D1. Prostaglandin D1 is a prostanoid which causes contractile and relaxant on isolated human pial arteries, it is also an inhibitor of ADP-induced platelet aggregation with an IC₅₀ value of 320 ng/ml. Prostaglandin D1 can be used for metabolic research .

HY-113113S

13,14-Dihydro PGE1-d4 13,14-Dihydroprostaglandin E1-d₄; PGE0-d₄	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
13,14-Dihydro PGE1-d₄ (13,14-Dihydroprostaglandin E1-d₄) is deuterium labeled 13,14-Dihydro PGE1. 13,14-Dihydro PGE₁ is a metabolite of PGE₁ (Prostaglandin E1) which inhibits the ADP-induced platelet aggregation (ID₅₀ = 10.8 ng/mL platelet rich plasma) .

HY-W009276R

γ-Linolenic Acid methyl ester (Standard) Methyl GLA (Standard)	Reference Standards Apoptosis	Cancer
γ-Linolenic Acid methyl ester (Standard) is the analytical standard of γ-Linolenic Acid methyl ester. This product is intended for research and analytical applications. γ-Linolenic Acid methyl ester (Methyl GLA) is an esterified version of γ-Linolenic Acid (GLA), which is an ω-6 fatty acid, serves as melanoma cell proliferation inhibitors. γ-Linolenic Acid methyl ester inhibits ADP-induced blood platelet aggregation and induces apoptosis .

HY-137355

15(S)-15-methyl Prostaglandin D2 15(S)-15-Methyl PGD2	Prostaglandin Receptor	Cardiovascular Disease Metabolic Disease
15(S)-15-methyl Prostaglandin D2 (15(S)-15-methyl PGD2) is a metabolically stable synthetic analog of PGD2. In contrast to PGD2, 15(S)-15-methyl PGD2 induces vasoconstriction and increases systemic blood pressure with much reduced inhibitory activity on ADP-induced platelet aggregation. It also exhibits strong antifertility activity in hamsters (200-fold more potent than PGD2).

HY-17459R

Clopidogrel hydrogen sulfate (Standard) (S)-(+)-Clopidogrel bisulfate (Standard); (S)-(+)-Clopidogrel hydrogen sulfate (Standard)	Reference Standards Cytochrome P450 P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel (hydrogen sulfate) (Standard) is the analytical standard of Clopidogrel (hydrogen sulfate). This product is intended for research and analytical applications. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC₅₀s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

HY-17459S

Clopidogrel-d3 hydrogen sulfate (S)-(+)-Clopidogrel bisulfate-d3; (S)-(+)-Clopidogrel-d3 hydrogen sulfate	P2Y Receptor Cytochrome P450	Cardiovascular Disease
Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate . Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC₅₀s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

HY-112658

p-Iodoclonidine hydrochloride	Adrenergic Receptor Adenosine Receptor	Endocrinology
p-Iodoclonidine hydrochloride is a partial agonist of α2-adrenergic receptor. p-Iodoclonidine hydrochloride also has minimal agonist activity in inhibiting adenylate cyclase in platelet membranes, and potentiates ADP induced platelet aggregation with an EC₅₀ of 1.5 μM .

HY-110057

FR 409 NOR 3	NO Synthase	Cardiovascular Disease
FK409 (NOR 3) is an oral active vascular relaxant agnet and can be isolated from microbial product. FK409 can be used for study of cardiovascular diseases .

HY-N17941

19-Anhydro-4-epirotungenic acid	Others	Cardiovascular Disease
19-Anhydro-4-epirotungenic acid is a triterpenoid compound that can be isolated from the bark of Ilex rotunda Thunb. 19-Anhydro-4-epirotungenic acid shows no activity against *ADP*-induced platelet aggregation .

Cat. No.	Product Name	Type

HY-W250153

Adenosine 3'-phosphate 5'-phosphosulfate lithium

Biochemical Assay Reagents

Adenosine 3'-phosphate 5'-phosphosulfate lithium, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

HY-W250153A

Adenosine 3'-phosphate 5'-phosphosulfate lithium, hydrate

Biochemical Assay Reagents

Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

Cat. No.	Product Name	Target	Research Area

HY-P0074

GPRP 3 Publications Verification Gly-Pro-Arg-Pro; Pefa 6003	Thrombin	Cardiovascular Disease
GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor) . GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of thrombin onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases .

HY-P1702

GR83895	Integrin	Others
GR83895 is a RGD based peptide, and inhibits ADP-induced platelet aggregation of human gel-filtered platelets (IC₅₀= 0.9 μM) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N5021

Anhydrosafflor yellow B AHSYB	Quinones Simple Phenylpropanols Carthamus tinctorius L. Phenols Polyphenols Benzene Quinones Phenylpropanoids Plants Compositae Source Classification	Others
Anhydrosafflor yellow B (AHSYB) is a quinochalcone C-glycoside isolated from Carthamus tinctorius. Anhydrosafflor yellow B inhibits ADP-induced platelet aggregation, exhibits significant anti-oxidative effects in vitro, and possesses certain activity against H₂O₂-induced cytotoxicity in cultured PC12 cells and primary neuronal cells .

HY-N3228

Myrianthic acid	Triterpenes Structural Classification Terpenoids Labiatae Ainsliaea acerifolia Nakai Plants Source Classification	Others
Myrianthic acid is a pentacyclic triterpenoid compound. Myrianthic acid can exist in the root wood of Myrianthus arboreus and the leaves of Campsis grandiflora. Myrianthic acid inhibits adrenaline-induced platelet aggregation, with a IC₅₀ of 46.2 μM for this activity. Myrianthic acid can be used in studies related to thrombosis .

HY-N7614

Anemarrhenasaponin A2 1 Publications Verification Schidigerasaponin F2; Timosaponin AII	Cardiovascular Disease Liliaceae Classification of Application Fields Anemarrhena asphodeloides Bunge Plants Disease Research Fields Steroids Source Classification	Others
Anemarrhenasaponin A2 (Schidigerasaponin F2) is a steroidal saponin isolated from the rhizomes of Anemarrhena asphodeloides. Anemarrhenasaponin A2 inhibits ADP-induced platelet aggregation .

HY-N13135

Kadsutherin G	Kadsura heteroclita (Roxb.) Craib Lignans Phenylpropanoids Plants Schisandraceae Source Classification	Others
Kadsutherin G (compound 3) is a lignin isolated from Kadsura. Kadsutherin G inhibits adenosine diphosphate (ADP)-induced platelet aggregation by 33.1 % .

HY-N13134

Kadsutherin F	Kadsura heteroclita (Roxb.) Craib Lignans Phenylpropanoids Plants Schisandraceae Source Classification	Others
Kadsutherin F (compound 2) is a lignin that can be isolated from Kadsura. Kadsutherin F has an inhibitory effect on adenosine diphosphate (ADP)-induced platelet aggregation with an inhibition rate of 49.47% .

HY-N4266

Vinaginsenoside R8	Cardiovascular Disease Panax ginseng C. A. Meyer Triterpenes Classification of Application Fields Terpenoids Plants Disease Research Fields Araliaceae Source Classification	Others
Vinaginsenoside R8, a triterpenoid glycoside isolated from the rhizomes of Panacis majoris. Vinaginsenoside R8 displays activities against adenosine diphosphate (ADP)-induced platelet aggregation (IC₅₀=25.18 μM) .

HY-N17941

19-Anhydro-4-epirotungenic acid	Aquifoliaceae Structural Classification Terpenoids Parameria laevigata (Juss.) Moldenke Plants Pentacyclic Triterpenoids Source Classification	Others
19-Anhydro-4-epirotungenic acid is a triterpenoid compound that can be isolated from the bark of Ilex rotunda Thunb. 19-Anhydro-4-epirotungenic acid shows no activity against *ADP*-induced platelet aggregation .

HY-N19129

Macrostemonoside E	Structural Classification Natural Products Allium macrostemon Bunge Plants Amaryllidaceae Source Classification	Others
Macrostemonoside E is a steroidal glycoside present in Allium macrostemon Bunge, which inhibits ADP-induced aggregation of human platelets in vitro (IC₅₀=0.417 mM) .

HY-N17826

YM-254891	Structural Classification Natural Products Microorganisms Source Classification	Drug Derivative Bacterial P2Y Receptor Endogenous Metabolite
YM-254891 is a YM-254890 (HY-111557) analogue and Gαq/11 inhibitor. YM-254891 can be isolated from the fermentation broth of Chromobacterium sp. QS3666. YM-254891 inhibits ADP-induced platelet aggregation .

HY-N19844

3-Heptadecylcatechol	Structural Classification Simple Phenylpropanols Phenols Polyphenols Phenylpropanoids Plants Toxicodendron vernicifluum (Stokes) F. A. Barkl. Anacardiaceae Source Classification	Others
3-Heptadecylcatechol is an urushiphenol compound found in Toxicodendron vernicifluum resin and poison oak urushiol. 3-Heptadecylcatechol exhibits anti-platelet aggregation and immune regulation activity. 3-Heptadecylcatechol can be used for the research of thrombotic disorders .

HY-N18260

Desmodilactone	Structural Classification Grona styracifolia (Osbeck) H. Ohashi & K. Ohashi Ketones, Aldehydes, Acids Plants Fabaceae Source Classification	P2Y Receptor
Desmodilactone is a P2Y1R allosteric antagonist. Desmodilactone can be used for the research of thrombosis .

Cat. No.	Product Name	Chemical Structure

HY-15284S2

Prasugrel-d4
Prasugrel-d₄ is the deuterium labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S1

Prasugrel-d3
Prasugrel-d₃ is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S

Prasugrel-d5
Prasugrel-d₅ is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S3

Prasugrel-13C6
Prasugrel-13C6 is a deuterated labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-113096S

Prostaglandin D1-d4
Prostaglandin D1-d₄ (PGD1-d₄) is deuterium labeled Prostaglandin D1. Prostaglandin D1 is a prostanoid which causes contractile and relaxant on isolated human pial arteries, it is also an inhibitor of ADP-induced platelet aggregation with an IC₅₀ value of 320 ng/ml. Prostaglandin D1 can be used for metabolic research .

HY-113113S

13,14-Dihydro PGE1-d4
13,14-Dihydro PGE1-d₄ (13,14-Dihydroprostaglandin E1-d₄) is deuterium labeled 13,14-Dihydro PGE1. 13,14-Dihydro PGE₁ is a metabolite of PGE₁ (Prostaglandin E1) which inhibits the ADP-induced platelet aggregation (ID₅₀ = 10.8 ng/mL platelet rich plasma) .

HY-17459S

Clopidogrel-d3 hydrogen sulfate

Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate . Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC₅₀s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

Cat. No.	Product Name		Classification

HY-W250153

Adenosine 3'-phosphate 5'-phosphosulfate lithium		Nucleotide Analogs Adenine Nucleotide
Adenosine 3'-phosphate 5'-phosphosulfate lithium, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

HY-164090

Adenosine 3'-phosphate 5'-phosphosulfate		Nucleotide Analogs Adenine Nucleotide
Adenosine 3'-phosphate 5'-phosphosulfate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

HY-W250153A

Adenosine 3'-phosphate 5'-phosphosulfate lithium, hydrate		Nucleotide Analogs Adenine Nucleotide
Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

ADP-induced aggregation

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products